how many people use glp-1 drugs peaks in middle age, then drops at 65 The GLP-1 Access Gap: Mapping

Zhang Y, Rahematpura S, Ragnini KH, Moreno A, Stecyk KS, Kahng MW, Milliken BT, Hayes MR, Doyle RP, Schmidt HD

Phentermine-topiramate works by affecting brain chemicals that control hunger and satiety

As a triple agonist, retatrutide stimulates three potent hormone receptors that control energy balance, metabolism, and weight: Glucagon-Like Peptide-1, or GLP-1: Diminishes appetite Delays the emptying of the stomach Enhances blood sugar regulation Glucose-Dependent Insulinotropic Polypeptide, or GIP: Improves the response to insulin Promotes metabolic adaptability Enhances the use of nutrients The glucagon receptor: Raises energy costs Encourages the burning of fat Aids in the mobilization of fat reserves Compared to single-agonist or dual-agonist therapies, the synergistic effect of these triple agonists results in more effective and long-lasting weight loss

Most of the drug typically leaves the body about 2530 days after the last injection

Levy, S